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Transplant Research
Naynesh R. Kamani,1 Shimareet Kumar,1 Anna Hassebroek,2 Mary Eapen,3
Jennifer LeRademacher,4 James Casper,5 Morton Cowan,6 Jose Sanchez de Toledo,7
Alina Ferster,8 Paul Szabolcs,9 John R. Wingard,10 Edwin Horwitz,11 Alexandra H. Filipovich12We describe the incidence of malignancy in patients with primary immunodeficiency disorders (PIDD)
following hematopoietic cell transplantation (HCT). From the Center for International Blood and Marrow
Transplant Research, 2266 PIDD patients who had undergone allogeneic HCT between 1968 and 2003
were identified. Patient, disease, and transplant factors for development of malignancy were examined
and pathology reports for reported malignancies reviewed independently by a pathologist for confirmation.
The incidence of malignancy was highest for Wiskott-Aldrich syndrome (3.3%), with an overall incidence of
2.3% for PIDD. Post-HCT malignancy was confirmed for 52 of 63 reported cases. Forty-five of 52 patients
developed posttransplant lymphoproliferative disorders (PTLD) at a median of 3 months post-HCT. Of
these, 26 had received T cell-depleted (TCD) bone marrow. Three patients who developed myelodysplastic
syndrome had received TCD marrow and total body irradiation. Three patients developed a solid tumor.
Patients with PIDD are at a relatively low risk of developing malignancies post-HCT compared with their
historic risk of cancer. The most frequent malignancy or lymphoproliferative disorder was early-onset
PTLD. As in other HCT recipients, TCD appears to correlate with PTLD development. Our results lend
support to the hypothesis that immune reconstitution in PIDD following HCT leads to a decrease in cancer
risk.
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Children with primary immune deficiency diseases
(PIDD) such as severe combined immune deficiency
(SCID) and Wiskott-Aldrich syndrome (WAS) die
prematurely as a result of serious infections or
malignancies. Although the number of children with
PIDD who develop cancer every year is small, it has
been estimated that the overall risk for cancer in these
children is about 4%, or about 10,000 times greater
than expected in age-matched healthy controls [1,2].
Allogeneic hematopoietic cell transplantation
(HCT) is currently the only curative therapy available
for a number of prematurely lethal PIDD. Since
1968, when the first successful allogeneic bone marrow
transplantation was reported in a child with SCID [3],
several thousand children with PIDD have undergone
HCT. SCID and WAS represent the most frequent
indications for allogeneic HCT among these patients.
Complete reconstitution of the immune system
with full donor hematopoietic chimerism can be
achieved in patients with PIDD after myeloablative1783
1784 Biol Blood Marrow Transplant 17:1783-1789, 2011N. R. Kamani et al.chemotherapy with or without irradiation and HCT.
It is not known whether this impacts the risk of
malignancies for these patients. We hypothesize that
allogeneic HCT for PIDD results in a decreased risk
of malignancy because of improved immune surveil-
lance as a result of achieving immune competence.
There is little specific data in the published
literature regarding the incidence of malignancies
post-HCT in patients with PIDD. Posttransplant
lymphoproliferative disorders (PTLD) have been re-
ported in a number of patients with SCID following
thymic epithelial transplants and haploidentical
T cell-depleted (TCD) bone marrow transplants
(BMTs) [4]. A retrospective analysis performed by
Neudorf et al. [5] in 1984 had documented no cases
of cancer in SCID patients following successful BMT.
Whether HCT decreases the risk of cancer in pa-
tients with PIDD is unknown. Little is known about
the incidence of cancer or the risk factors associated
with development of cancer in these HCT survivors.
Here, we present a descriptive report of risk factors
that may have contributed to the development of
a malignancy after allogeneic HCT in a large cohort
of children with PIDD reported to the Center for In-
ternational Blood and Marrow Transplant Research
(CIBMTR).Table 1. Patients with PIDD Reported to CIBMTR
(1968-2003)
Variable N (%)
Patients 2266
Diagnosis
Wiskott-Aldrich Syndrome 360 (16)
SCID 1075 (47)METHODS
Data Collection
The CIBMTR is a working group of over
500 transplant centers worldwide that voluntarily
contribute detailed patient, disease, and, transplant
characteristics and outcome data on HCT recipients
to a Statistical Center at the Medical College of
Wisconsin. Participating centers register consecutive
transplants and provide relevant patient, disease, and
transplant characteristics and outcome data including
graft-versus-host disease (GVHD), development of
malignancy post-HCT, survival, and for deceased
patients, cause of death. Detailed demographic, dis-
ease, and transplant characteristics as well as outcome
data are collected on allogeneic transplants. Patients
are followed annually until death. Computerized error
checks, physician review of submitted data, and on-site
audits of participating centers ensure data quality. This
study was approved by the institutional review board of
the Medical College of Wisconsin.Other 831 (37)
Patients with confirmed malignancy
reported to CIBMTR
52
Wiskott-Aldrich Syndrome 12/360 (3.3)
SCID 25/1075 (2.3)
Other 15/831 (1.8)
PIDD indicates patients with primary immunodeficiency disorders;
SCID, severe compromised immunodeficiency; CIBMTR, Center for
International Blood and Marrow Transplant Research.Statistical Analysis
The incidence of malignancy post-HCT was de-
termined using the cumulative incidence estimator
with death as the competing risk. Ninety-five percent
confidence intervals were calculated using standard
techniques [6].Patients
The study population consisted of 2266 patients
with PIDD who had undergone allogeneic HCT be-
tween 1968 and 2003 and reported to the CIBMTR
(Table 1). Included are recipients of matched and
mismatched related donor and unrelated donor trans-
plants. Patients’ ages ranged from 1.2 months to 47
years, with a median age of 1 year. The 2 most
common indications for transplantation for PIDD
were SCID (47%) and WAS (16%). As a result,
approximately 80% of patients were male.
Sixty-three patients reportedly developed a new
malignancy after HCT. Because of the inclusive dates
of the analysis, and the fact that the CIBMTR does
not maintain a tissue bank, it was deemed impracticable
to retrieve and review slides on biopsy/autopsy
specimens to confirm the diagnosis of a malignancy.
Therefore, post-HCT malignancy was confirmed in
52 patients using pathology reports and/or confirming
with the transplant center. There was insufficient
information to confirm the diagnosis of malignancy in
11 patients. To avoid reporting bias, patients trans-
planted at inactive centers or centers that did not
respond to requests to participate were excluded from
the analysis (n5 143 patients from7 transplant centers).RESULTS
Table 2 shows the characteristics of patients
with PIDD who developed malignancy post-HCT
compared with those who did not. Fifty-two of 2266
patients were confirmed to have developed posttrans-
plantation malignancy. Patient, disease, and transplant
characteristics of these patients are shown in Table 3.
The 5-year, 10-year, and 15-year cumulative incidence
of post-HCTmalignancy was 2% (95% confidence in-
terval [CI]: 2%-3%), 2% (95% CI:2%-3%), and 3%
(95% CI:2%-5%), respectively. The corresponding
cumulative incidence for patients with SCID was
2% (95% CI:1%-3%) at 5 and 10 years and 3%
(95% CI:1%-6%) at 15 years; for WAS, 4% (95%
Table 2. Characteristics of Patients Undergoing Trans-
plantation for a Primary Immune Deficiency and Registered
with the CIBMTR before 2003
Characteristics
No Malignancy
Post-tx
Malignancy
Post-tx
P*N (%) N (%)
Number of patients 2214 52
Disease 0.27
SCID 1050 (47) 25 (48)
WAS 348 (16) 12 (23)
Other ID † 816 15
Phagocyte disorders 208 (9) 5 (10)
Combined immunodeficiency
disorders
278 (13) 6 (12)
T cell disorders 28 (1)
Other ID, not specified 302 (14) 4 (8)
SCID Phenotype 0.83
SCID ADA deficiency 129 (12) 2 (8)
SCID absent T and B cells 271 (26) 7 (28)
SCID absent T, normal B cells 317 (30) 8 (32)
Omenn syndrome 74 (7) 3 (12)
Reticular dysgenesis 14 (1) 0
SCID, not specified 245 (23) 5 (20)
Donor 0.001
HLA-id sib 630 (28) 1 (2)
Other relative 932 (42) 29 (58)
Unrelated 519 (23) 19 (33)
Fetal ‡ 91 (4) 3 (5)
Other/missing 42 (1)
T cell depletion § 0.002
No 999 (45) 12 (23)
Yes 1045 (47) 40 (77)
Missing 170 (8) 0
Type of malignancy
posttransplantation
PTLD 45 (87)
AML/MDS 4 (8)
Solid tumor 3 (6)
Year of transplantation 0.14
#1980 174 (8) 1 (2)
1981-1990 510 (23) 18 (35)
1991-1999 1073 (48) 23 (44)
2000-2003 457 (21) 10 (19)
Survival status
Alive 1365 (62) 12 (23)
Dead 849 (38) 40 (77)
Median follow-up of survivors,
years (range)
4.6 (<1-30) 7 (4-14)
SCID indicates severe combined immunodeficiency; WAS, Wiskott-
Aldrich Syndrome; PTLD, posttransplant lymphoproliferative disease;
AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome.
*Chi-square test.
†Phagocyte disorders include chronic granulomatous disease, Chediak-
Higashi syndrome, and leukocyte adhesion deficiencies; combined
immunodeficiency disorders include X-linked lymphoproliferative
syndrome, cartilage hair hypoplasia, immune deficiency plus neutropenia,
CD40 ligand deficiency, common variable immunodeficiency, other com-
bined immunodeficiencies, bare lymphocyte syndrome, and ataxia telangi-
ectasia; T cell disorders include HIV infection and DiGeorge anomaly.
‡Fetal tissue refers to the use of fetal liver, thymus, or other fetal tissue
(not cord blood).
§T cell depletion includes in vivo and/or ex vivo T cell depletion. The
P values need to be interpreted with caution because data on TCD
was missing in a large number of patients.
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2% (95% CI:1%-3%) at 5 years and 2% (95%
CI:1%-4%) at 10 and 15 years. With a median
follow-up of 6 years (range: 4-14), 12 patients werealive. Forty patients (77%) are dead; death was
attributed to the posttransplantation malignancy in
29 patients. Other causes of death include GVHD
(n 5 3), infection without GVHD (n 5 4), and the
cause of death was not reported for 4 patients.
Lymphoproliferative disorders (LPD) ranging
from PTLD to a non-Hodgkin lymphoma was the
most commonmalignancy and occurred in 45 patients.
Epstein-Barr virus (EBV)-induced LPD was con-
firmed in 17 of these patients. GVHD prophylaxis or
treatment for the 45 patients with PTLD consisted
of TCD in 35 (78%) patients. Of these, 12 received
TCD bone marrow graft, 13 received TCD bone mar-
row graft and in vivo antithymocyte globulin (ATG),
1 patient received a TCD peripheral blood stem cell
(PBSC) graft and in vivo ATG, and the remaining
9 patients received in vivo ATG only. Only 5 patients
received total body irradiation (TBI). The median
time to development of the LPD was 3 months from
transplantation (range: 1-41 months).
Three patients developed myelodysplastic syn-
drome (MDS) and 1 patient, acute myeloid leukemia
(AML); these developed in patients with non-SCID
PIDD. All 3 MDS patients had received TBI (1320-
1400 cGy) as part of their conditioning regimen
and a TCD bone marrow graft. The patient who
developed AML received ATG as part of the condi-
tioning regimen, and 1 patient with MDS received
ATG for treatment of acute GVHD (aGVHD). The
median time to development of the MDS or AML
was 34 months (range: 9-55 months). Patient ID #5
with WAS who underwent a sex-matched TCD unre-
lated donor HCT developed MDS 55 months post-
HCT. Cytogenetics showed numerous structural
abnormalities but was unable to resolve the source of
the malignant clone. Patient ID #16 with Chediak-
Higashi syndrome developed MDS 44 months after
a TCD-unrelated donor transplant. Bone marrow
showed multiple cytogenetic abnormalities (including
del7q and del 20q) distributed among 4 independent
clones whose origin could not be determined.
Whether these were present pre-HCT could not be
confirmed because the pretransplantation bone mar-
row failed to yield metaphases. The bone marrow did
show rare mononuclear cells with abnormal Chediak
granules, suggesting residual host cells. Patient ID
#17 with WAS underwent a sex-mismatched TCD-
unrelated donor HCT. He developed MDS 23 months
post-HCT, and his bone marrow had 80% recipient
and 20% donor cells, with 1 of the recipient clones
showing a del(7) abnormality.
Three patients developed a solid tumor. One
patient with Omenn syndrome developed desmoplastic
squamous cell carcinoma of the right foot 170 months
after unrelated donor HCT; 1 patient with CID
developed hepatocellular carcinoma 84 months after
unrelated donor HCT; and the remaining patient
Table 3. List of 52 Patients with Confirmed Malignancy/Lymphoproliferative Disorder
ID Diagnosis
Age at Transplantation
(Months) Donor Graft Source Preparative Regimen GVHD Prophylaxis aGVHD cGVHD
Interval*
(Months) Status Posttransplantation Malignancy
1 SCID 12 MRD BM CY T-depletion No No 38.9 Dead EBV-PTLD
2 CID 18 Haplo Id BM None T-depletion No No 2.9 Dead Immunoblastic BCL
3 WAS 18 Haplo Id BM BU + CY+ATG T-depletion Gr 2 No 1.5 Dead EBV-PTLD
4 SCID 6 Haplo Id BM None T-depletion No No 16.4 Dead Large cell lymphoma
5 WAS 32.4 1 Ag MM URD BM Cy + TBI T-depletion Gr 1 No 55.2 Dead MDS
6 Immune-unclassified 6 Haplo Id BM BU + CY T-depletion Gr 2 No 26.9 Dead PTLD
7 SCID 7.2 Haplo Id BM None T-depletion Gr 2 Yes 26.2 Dead BLPD
8 SCID 7.2 Haplo Id BM Cy + TBI+ATG T-depletion No No 2.5 Dead PTLD
9 SCID 20.4 Haplo Id BM BU + CY+ATG T-depletion No No 1.3 Dead PTLD
10 SCID 18 1 Ag MM URD BM BU + CY+ATG CSA + MTX Gr 4 Yes 2.2 Dead EBV-PTLD
11 SCID 8.4 Haplo Id BM BU + CY+ATG T-depletion Gr 1 No 2.2 Alive B cell LPD
12 SCID 15.6 Haplo Id BM BU + CY+ATG T-depletion Gr 2 No 2.9 Dead EBV-PTLD
13 WAS 12 Haplo Id BM BU + CY+ATG T-depletion Gr 3 No 3.7 Dead PTLD
14 SCID 6 Haplo Id BM CY + ATG T-depletion Gr 3 No 2.7 Dead Monoclonal BCL
15 Omenn syndrome 1.2 1 Ag MM RD BM None None No No 3.7 Dead Malignant lymphoma
16 CHS 14.4 MUD BM Cy + TBI T-depletion Gr 2 Yes 44.9 Alive MDS
17 WAS 21.6 MUD BM Cy + TBI T-depletion Gr 2 Yes 23.2 Alive MDS/AML
18 SCID 39.6 1 Ag MM URD BM BU + CY+ATG T-depletion No No 3.7 Dead EBV-PTLD
19 LAD 19.2 Haplo Id BM BU + CY T-depletion Gr 1 No 36.3 Dead Immunoblastic BCL
20 SCID 1.2 MSD BM CY + ATG CSA + other No No 2.1 Dead EBV-PTLD
21 CVID 152.4 MUD BM Cy + TBI T-depletion Gr 3 Yes 1.9 Alive BLPD
22 Kostmann 88.8 1 Ag MM URD CB Bu+Cy+ATG CSA + other Gr 2 No 7.4 Alive BLPD-LBCL
23 SCID 14.4 1 Ag MM RD BM BU + CY+ATG T-depletion Gr 4 Yes 15.4 Alive High Grade NHL
24 WAS 265.2 MUD BM Cy + TBI+ATG CSA + MTX Gr 1 No 1.6 Dead EBV-PTLD
25 SCID 24 1 Ag MM URD BM Fludarabine CSA + MTX Gr 2 No 2.6 Dead PTLD
26 SCID 195.6 2 Ag MM URD CB Cy + Flud + ATG CSA + other No No 0.9 Dead EBV-PTLD
27 WAS 55.2 URD BM BU + CY+ATG CSA + MTX No Yes 3.6 Alive Immunoblastic BCL
28 Omenn syndrome 7.2 MUD BM Cy CSA + MTX Gr 2 Yes 169.6 Alive Desmoplastic squamous cell, R. foot
29 SCID 7.2 Haplo Id BM Cy T-depletion Gr 2 No 2.0 Alive EBV-PTLD
30 SCID 4.8 Haplo Id BM None NR No No 1.8 Dead EBV-PTLD
31 WAS 93.6 RD NR NR NR NR NR 19.7 Dead Large cell malignant lymphoma EBV +
32 ID, NOS 20.4 RD PBSC Mel+Thio+Flud+ATG T-depletion NR NR 1.0 Dead Diffuse large B-cell Lymphoma EBV +
33 WAS 64.8 URD BM BU + CY+ATG Corticosteroids + other NR NR 1.5 Dead B cell lymphoma EBV positive
34 CID 20.4 RD BM BU + CY None NR NR 14.2 Alive EBV PTLD
35 WAS 15.6 URD CB BU + CY+ATG CSA + other NR NR 9.4 Dead PTLD
36 CHS 84 RD BM BU + CY CSA + MTX NR NR 9.9 Dead EBV PTLD
37 SCID 6 RD BM CY + ATG T-depletion NR NR 1.3 Dead Lymphoma, EBV undetermined
38 SCID 4.8 Fetal Fetal None None No No NR Dead Brain tumor
39 SCID 10.8 Fetal Fetal None None No No 41.0 Dead Hodgkin lymphoma
40 CID 4.8 Fetal Fetal None None No No NR Dead Lymphoma
41 SCID 4.8 Haplo Id BM Cy+ARAC T-depletion No No NR Dead EBV-PTLD
42 WAS 8.4 Haplo Id BM BU + CY T-depletion No No 8.4 Dead B cell lymphoma
43 WAS 40.8 Haplo Id BM Cy + TBI T-depletion No No 1.1 Dead EBV-PTLD
44 WAS 13.2 MUD BM BU + CY+ATG T-depletion Gr 2 No 19.4 Dead B cell lymphoma
45 Immune-unclassified 111.6 1 Ag MM URD BM Cy + TBI+ATG T-depletion No No 3.0 Dead EBV-PTLD
46 X-linked lymphoproliferative
syndrome
93.6 MUD CB BU + CY+ATG CSA + other Gr 4 Yes 5.4 Dead EBV-PTLD
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Biol Blood Marrow Transplant 17:1783-1789, 2011 1787Malignancies after HCT for Immune Deficienciesdeveloped a brain tumor afterHCT for SCID, although
the time to tumor development was not reported.DISCUSSION
The etiology of cancer in childhood is multifacto-
rial. An important factor that contributes to an in-
creased incidence of cancer in children is the presence
of underlying immunodeficiency, either inherited or
acquired [1]. Improved treatments and supportive
care as well as allogeneic HCT for the PIDD have re-
sulted in significant improvements in survival for these
children. The Immunodeficiency-Cancer Registry was
set up in 1973 to track the incidence of cancers in
patients with PIDD. As of August 1986, 514 cases of
malignancy had been registered in patients with
PIDD. Of these, almost half were non-Hodgkin
lymphoma, with leukemia or Hodgkin’s disease
accounting for another 20% of cases. Nine percent of
the cases were adenocarcinomas, and other tumors
accounted for the remainder. Although over one-half
of these tumors occurred in patients with Ataxia-
Telangiectasia (AT) (30%) and common variable
immunodeficiency (24%), about 25% were seen in
patients with WAS and SCID [7-9]. A recent analysis
of data reported to the Australasian Society of
Clinical Immunology and Allergy PID Registry
showed that although there was a 1.6-fold excess rela-
tive risk of cancer observed for PID patients, the
standardized incidence ratio (SIR) was 5.36 to 8.82
for non-Hodgkin lymphoma, leukemia, and stomach
cancer. The SIRs for all cancers were significantly
increased in patients with common variable immuno-
deficiency (CVID) and AT [10].
Patients with leukemia or aplastic anemia who
have undergone BMT are at a significantly higher
risk of developing a secondary cancer compared with
age-matched healthy controls [11]. In a recent analysis
of over 18,000 BMT recipients by Curtis et al. [12], the
cumulative incidence of PTLD was 1.0 6 0.3% at
10 years after HCT with the highest incidence in
the first 5 months post-HCT. Patients with non-
Hodgkin lymphoma, Fanconi anemia, and PIDD
were excluded from this analysis.
Although our analysis can only serve to assess the
risk factors that contribute to the development of
a malignancy post-HCT for PIDD, the overall inci-
dence of malignancies in transplanted PIDD patients
(52 of 2266, or 2.3%) is lower than what has been re-
ported in previous reports of patients with PIDD.
LPD constitutes the most frequent malignancy in pa-
tients with PIDD, especially those with WAS, com-
mon variable immune deficiency, AT, and SCID.
It has been estimated that the risk of malignancy
in WAS, CVID, and AT may be 100 times that of
the general population. Because patients with SCID
1788 Biol Blood Marrow Transplant 17:1783-1789, 2011N. R. Kamani et al.invariably die in infancy or early childhood without
successful HCT, there is little data on the long-term
incidence of malignancies in nontransplanted patients.
However, the median survival of patients with WAS
who do not undergo HCT has been estimated to be
in the late teens. Two large analyses of WAS patients
by Perry et al. [13] and Sullivan et al. [14] reported
development of a malignancy in 12% and 13% among
301 and 154 WAS patients, respectively.
Of the 52 malignancies reported here, 45 (87%)
were lymphoproliferative disorders. In the report by
Curtis et al. [12] discussed above, the risk of early
PTLD was strongly associated with TCD of donor
marrow (relative risk [RR] 5 12.7), and the use of
ATG (RR 5 6.4) or anti-CD3 monoclonal antibody
(RR 5 43.2) for prophylaxis or treatment of acute
GVHD. In our analysis, TCD clearly contributed as a
significant risk factor for the development of LPD.
Because the most frequent malignancies/lymphoproli-
ferative disorders reported in nontransplanted patients
with PIDD are LPD [15,16], it is difficult to assess the
relative contributions of the underlying immune
deficiency, the preparative regimen, and the TCD
to LPD development. However, the median time of
3 months between the HCT and the LPD is very
similar to the findings of Curtis et al. [12] and sug-
gests that the TCD was an important contributory
risk factor. There was no correlation between inci-
dence of PTLD and year of transplantation (data
not shown). EBV monitoring was not routinely avail-
able for the majority of patients transplanted during
the period covered by this report. Of the 52 patients
reported here, 40 died after developing a malig-
nancy/lymphoproliferative disorder, with the major-
ity of the deaths being attributed to the malignancy.
With routine monitoring for EBV reactivation with
EBV polymerase chain reaction (PCR) and preemp-
tive therapy, future analyses may allow us to assess
the impact of these approaches on the incidence and
survival of PTLD in these patients.
An analysis of 19,229 patients who had received
allogeneic or syngeneic transplantations for acute
and chronic leukemias and a number of nonmalignant
diseases identified a cumulative incidence of new solid
cancers of 2.2% at 10 years and 6.7% at 15 years. The
use of TBI and the presence of chronic GVHD
(cGVHD) were associated with a higher risk of solid
cancers, and there was a trend toward an increased
risk of solid cancers over time, with younger patients
having the greatest risk of developing solid cancers
post-HCT [17]. However, patients with Fanconi ane-
mia and primary immune deficiencies were excluded
from this analysis because of their inborn susceptibility
to cancer. In a separate analysis of 700 patients with
severe aplastic anemia including 79 with Fanconi
anemia, Deeg et al. [18] reported 23 malignancies
post-HCT. There were 5 cases of lymphoid malignan-cies at a median of 3 months posttransplantation and
18 cases of solid tumors at a median of 99 months
post-HCT. In this analysis, the most significant risk
factor for solid tumors was Fanconi anemia, consistent
with the known risk of solid tumors in nontransplanted
Fanconi anemia patients.
There are a number of limitations to our analysis
that need to be acknowledged. Centralized histopatho-
logic examination of archived tissue or slides on each of
the patients would have been the ideal way to confirm
the occurrence of a malignancy. Because a large num-
ber of these patients had been diagnosed over 20 years
earlier, it was considered impracticable to retrieve these
specimens, and we chose to review clinical and pathol-
ogy reports to confirm the malignancy. Second,
although data are available for the risk of malignancy
in a cohort of age-matched healthy children, the true
comparator for our cohort of patients with primary
immune deficiencies would have been a similarly sized
cohort of patients with PIDD who had not undergone
transplantation. Unfortunately, reliable data on such
a cohort are not available. For assessment of the impact
of HCT on the risk of malignancy in PIDD, one has to
thus rely on early data from the Immunodeficiency-
Cancer Registry and data compiled throughmultiinsti-
tutional surveys of patients with WAS.
We conclude from this analysis that patients with
primary immune deficiencies who undergo HCT
appear to be at a relatively low risk of developing
malignancies compared with the historic risk of
cancer in these patients. The most frequent malig-
nancy/lymphoproliferative disorder seen in this
cohort of patients is that of early-onset PTLD, and
as has been noted for other HCT recipients, the use
of TCD appears to correlate with the development
of PTLD posttransplantation.ACKNOWLEDGMENTS
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